Insect-borne diseases Archives

Themis Biosciences fundraising chikungunya vaccine

News and Trends 18 Sep 2019

Themis Raises €40M for First Phase III Trial of a Chikungunya Vaccine

Vienna-based Themis Biosciences has raised €40M in a Series D round to fund a phase III trial that could lead to the approval of the world’s first vaccine for chikungunya infection. The round, one of the largest seen in Austrian biotech so far, was co-led by two new investors, Farallon Capital and Hadean Ventures. […]

September 18, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jun 2019

Austrian Biotech Raises €19M to Commercialize First Chikungunya Vaccine

The market is in sight for the first potential vaccine for the chikungunya virus, as the company Themis Bioscience will receive up to €18.7M ($21M) in non-dilutive funding to finance the vaccine’s phase III development. The money will cover most of the costs of the phase III trial, which Themis expects to begin later this […]

June 4, 2019 - 2 minutesmins - By Jonathan Smith

chikungunya virus mosquito Themis bioscience

News and Trends 6 Nov 2018

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

The mosquito-borne chikungunya virus may one day have a vaccine, as an Austrian biotech’s lead candidate gets positive results in Phase II. Themis Bioscience measured the blood levels of antibodies against the company’s vaccine in 263 healthy volunteers. Four weeks after injections of its lead candidate vaccine, the participants had produced antibodies to protect themselves […]

November 6, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Jan 2018

No More Mosquito Bites? Targeting These Genes Could Prevent Future Outbreaks!

Researchers may have found a way to stop the female mosquitoes from biting you, which could help to prevent the spread of diseases like malaria. Scientists at the University of Birmingham in the UK and the University of Notre Dame in Paris, along with collaborators in the US, have identified 902 genes specific to blood-feeding mosquitoes […]

January 22, 2018 - 3 minutesmins - By Alex Dale

Best in Biotech 27 Dec 2017

The Biggest Biotech News of 2017: What Happened This Year?

Still catching up on news? We’ve picked out the most exciting things that happened besides clinical results and finance. Here’s the biggest biotech news of 2017. We’ve been recapping the year with the most stellar biotechs, most heartening clinical successes and most disappointing failures in biotech. But what else happened this year? There’s more news […]

December 27, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 5 Dec 2017

The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons

Following alarming research about the safety of Sanofi’s dengue vaccine, Dengvaxia, The Philippines has halted its sale, distribution and marketing “to protect the general public.” Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would make people sicker. Last year, researchers from top American and British institutions confirmed these suspicions […]

December 5, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 6 Nov 2017

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya […]

November 6, 2017 - 3 minutesmins - By Alex Dale

News and Trends 5 Sep 2017

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever in a new Phase I/II trial sponsored by the NIH. Based in Vienna, Themis Bioscience develops new vaccine candidates for emerging diseases like Zika and Chikungunya with its virus […]

September 5, 2017 - 3 minutesmins - By Melanie De Almeida

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […]

July 25, 2017 - 6 minutesmins - By Evelyn Warner

Startup Scout 23 Jun 2017

This Newly Founded French Biotech is All About Vaccines

This week we visited the biotech hub Lyon, where one of our top biotechs Imaxio has recently founded Osivax to advance the development of its innovative vaccine candidates. Mission: Osivax was formed as a spin-off of Imaxio’s R&D department and develops a number of clinical and preclinical vaccine candidates based on its OligoDOM technology. This approach fuses specific immunogenic domains to […]

June 23, 2017 - 1 minutemin - By Melanie De Almeida

Interview 21 Jun 2017

Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry

In our fireside chat with Hadyn Parry, Clara had the chance to hear all about Oxitec’s exciting technology that could save us from Dengue and Zika. Oxitec’s GM mosquitoes have the potential to halt epidemics of mosquito-borne diseases such as Zika or Dengue, which according to Hadyn are actually causing more problems every year. As Hadyn explained, “we’re […]

June 21, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 3 Apr 2017

New Results Show GM Mosquitoes Keep Dengue and Zika at Bay in Brazil

In its second year, Oxitec has reduced the mosquito population in a Brazilian neighborhood by 81%, demonstrating the long-term potential of GM insects. Oxitec is a spin-out from the University of Oxford that fights infectious disease with genetically-engineered mosquitoes that produce inviable offspring. The company has already made field trials in the Cayman Islands, Panama, Brazil, […]

April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us